Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the largest study of its kind, a team of researchers led by MORU and WWARN in Bangkok developed a pharmacokinetic model that enabled a revised dose regimen to safely treat all malaria patients including young children with dihydroartemisinin-piperaquine (DP), a widely used antimalarial and a first-line treatment against malaria recommended by the World Health Organization (WHO).

Researcher in a lab
Pharmacokinetic Laboratory, Bangkok. Credit: Joss Dimock, Wellcome Images

Bangkok, 16 Jan 2017 – In the largest study of its kind, a team of researchers led by MORU and WWARN in Bangkok developed a pharmacokinetic model that enabled a revised dose regimen to safely treat all malaria patients including young children with dihydroartemisinin-piperaquine (DP), a widely used antimalarial and a first-line treatment against malaria recommended by the World Health Organization (WHO).

Results from the study, published in PLOS Medicine, have already been used by the WHO expert review panel’s decision to update its Guidelines for the treatment of malaria.

“It’s crucial to develop optimised dosing regimens to ensure appropriate drug exposure in all patient groups,” says Prof Joel Tarning, senior author of the study and Head of Clinical Pharmacology at MORU. “This revised dose regimen of dihydroartemisinin-piperaquine is intended to provide equivalent piperaquine exposures safely in all patients, including in small children with malaria. It’s an important step towards giving all patients an equal chance of cure.”

Similar stories

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19